As our understanding of cardiovascular disease has advanced over the past decades, multiple novel treatment strategies have been developed with the hope of reducing the global morbidity and mortality associated with this condition. Large-scale trials to test such novel therapies using clinical end points are expensive, leading to interest in phase II clinical trials with imaging-derived outcome measures.
INTRODUCTION
Recent advances in cardiovascular imaging have equipped researchers and clinicians with the ability to investigate many distinct features of the atherosclerotic disease process. In particular, we now have the capacity to quantify disease burden, to detect adverse plaque characteristics and, most recently, to assess disease activity. Measuring the impact of novel drug therapies on each of these key features can provide early insights into their likely clinical safety and efficacy. Whilst initially confined to the carotid and aorta, the evolution of sophisticated imaging techniques has recently extended advanced imaging to the coronary arteries.
Approval of novel drugs generally requires demonstration of an improvement in hard clinical outcomes within large phase III randomized controlled trials. However, such studies demand large patient numbers and long follow-up periods to demonstrate a clinical effect. They are therefore extremely expensive. This, coupled with the recent failure of several novel drugs to demonstrate benefit, has led to growing interest in intermediate clinical studies, which may help screen therapies most likely to be effective or ineffective. Furthermore, early indications of drug toxicity are of paramount importance before the initiation of phase III studies involving large populations of patients. Noninvasive imaging has an important role to play in both these respects, allowing direct visualization of the atherosclerotic disease process, and an appreciation of how this changes in response to therapy. Moreover, the development of hybrid scanners provides the opportunity to investigate simultaneously multiple different aspects of the disease process, providing greater insight into the action of novel therapies.
In this review, we will first briefly discuss the advantages of noninvasive compared with invasive imaging, before providing an overview of established noninvasive techniques, which facilitate the assessment of carotid plaque burden and characteristics. Finally, we will discuss novel strategies that can provide similar anatomical assessments in the coronary arteries, while incorporating advanced molecular assessments of disease activity. Ultimately, we believe that a hybrid noninvasive imaging approach will emerge as the most effective and comprehensive assessment of drug action, providing early indications of safety and efficacy.
Invasive versus noninvasive imaging in intervention trials
Some of the earliest studies examining the effects of medication on atherosclerotic plaque were performed using invasive imaging. In particular, intravascular ultrasound was used to quantify the effect of lipid lowering and antihypertensive therapy on plaque burden [1, 2] . Intravascular ultrasound provides high spatial-resolution images of the arterial wall, enabling an accurate assessment of luminal dimensions, atheroma volume and plaque burden, which can then be used to quantify therapeutic efficacy. This has provided evidence of the incremental benefit of intensive versus moderate lipid lowering [3] , and documented the effects of alternative therapies on atheroma progression [4] [5] [6] . More sophisticated invasive approaches have also been adopted in phase II studies, including the use of optical coherence tomography to assess the effect of drugs on fibrous cap thickness and near infrared spectroscopy to assess the lipid core burden index [7, 8] .
Whilst invasive imaging offers unparalleled spatial resolution, its widespread use in research is limited by a small, yet significant, risk of complications. Furthermore, intravascular imaging can be time-consuming and depends on the ability to safely pass the imaging catheter down the coronary lumen. Thus, serial invasive imaging studies often do not incorporate the entire coronary vasculature and are instead limited to specific coronary territories free from critical stenoses.
Noninvasive imaging, on the other hand, provides the opportunity to safely perform serial imaging of the entire vascular bed with a very low or absent risk of serious complication. Multiple different noninvasive techniques are available, each providing distinct information and possessing unique advantages and disadvantages (Table 1) .
CAROTID IMAGING
Most data from noninvasive cardiovascular intervention trials have been derived from the study of the carotid arteries. Indeed, the large calibre and stationary nature of the carotid vessels means they are particularly well suited for noninvasive imaging. Furthermore, histological validation can be obtained from carotid endarterectomy specimens.
For this reason, many trials investigating the treatment of atherosclerosis have studied carotid atheroma as a surrogate marker of coronary disease. Indeed, whilst the majority of cardiovascular-related deaths occur as a direct consequence of coronary atherosclerosis, the systemic nature of this disease means that the assessments of atheroma burden and disease are of relevance to the vascular tree as a whole [9] .
Carotid ultrasound
Carotid ultrasound is a simple and accessible screening tool that informs about plaque burden using measurements of the intimal medial thickness or total atheroma volume. Recent data have confirmed the important prognostic information provided by carotid plaque burden, highlighting the equivalent risk prediction provided by this method when compared directly with coronary computed tomography (CT) calcium scoring [10 & ]. Carotid intimal thickness has been utilized as a surrogate measure of atherosclerotic disease burden in trials assessing the impact of lipid lowering therapy on cardiovascular disease [11, 12] . Given the low cost, safety and accessibility of carotid ultrasound, it is very attractive
KEY POINTS
Noninvasive imaging has greatly contributed to our understanding of how antiatherosclerotic therapies work, providing direct visualization of plaque burden, plaque morphology and atherosclerotic disease activity.
Continued advances in imaging technology, particularly with the evolution of hybrid imaging, now allow assessment of each of these parameters in a single scan. Moreover, techniques to measure each of these features in the coronary arteries are developing rapidly.
In the future studies, hybrid imaging is likely to adopt a central role both in the carotid arteries using FDG-PET/ MR and PET/CT with novel radiotracers in the coronary arteries.
Noninvasive imaging is likely to play a central role in the future development and approval of novel therapies directed against atherosclerosis.
as a screening tool for large populations of patients in the community. However, it lacks accuracy compared with more sophisticated techniques, thus its use in future studies to assess the efficacy of novel drugs may be limited.
Magnetic resonance of the carotid arteries
Magnetic resonance (MR) is an attractive modality for cardiovascular intervention trials due to the possibility of performing serial imaging to track the effect of therapies across multiple vascular territories without the risks associated with radiation exposure [13 && ]. High spatial-resolution imaging of the carotid vessels is readily feasible, with accurate, reproducible measurements of carotid plaque thickness, volume and area derived from black-blood imaging sequences.
In common with ultrasound, these measures of carotid plaque burden predict major adverse cardiovascular outcomes [14, 15] and have already been used in several studies to investigate the time course of atherosclerotic regression in response to lipid lowering therapy [16] [17] [18] . Furthermore, MR plaque burden measurements have been utilized in trials comparing different doses of lipid lowering therapy, highlighting the increased efficacy of aggressive versus conservative lipid lowering in plaque regression [19 & ,20,21] . The excellent reproducibility of plaque burden measurements within the carotid arteries means that positive drug effects can be appreciated despite small patient numbers, making this technique an attractive end point for clinical trials from a cost-effectiveness perspective [20, 21] .
Along with quantification of plaque burden, high spatial-resolution multicontrast MRI provides detailed information regarding plaque composition based upon the distinct paramagnetic properties of different tissue types. It is well recognized that atherosclerotic plaques which are prone to rupture exhibit distinct characteristics including a large lipid necrotic core, thin fibrous cap, angiogenesis and microcalcification [22] . MRI can detect many of these features of vulnerability in the carotid arteries ( Fig. 1 
], providing an opportunity to investigate changes in plaque composition and therefore to investigate the plaque stabilizing effects of therapies.
Previous intervention trials have quantified the lipid burden and necrotic core of carotid plaque and demonstrated both a reduction in lipid content and increase in fibrous tissue following intensive lipidlowering therapy [18, 24, 25] . Longitudinal scanning has enabled appreciation of the time course of this effect, highlighting that the depletion of plaque lipid occurs in advance of a reduction in total plaque volume [18, 24, 25] . This suggests that MR-derived measures of lipid core may be more sensitive to treatment effects than plaque burden measurements and therefore of added value in future cardiovascular intervention trials.
Along with quantifying the lipid core, MR can be used to identify intra-plaque haemorrhage and endothelial thrombus associated with plaque rupture or erosion. In the presence of acute thrombus or haemorrhage, the formation of methaemoglobin leads to profound T1 shortening and results in high intensity signals on T1-weighted imaging sequences. This has been well demonstrated in the carotid arteries of patients who have suffered a recent stroke [26, 27] , and is associated with a six-fold increase in future cerebrovascular events [28] . Whether this high-risk plaque imaging characteristic within the carotids is modifiable with therapy remains to be 
CORONARY IMAGING
The majority of adverse cardiovascular events arise in the coronary arteries. Direct imaging of this vascular bed therefore remains desirable even despite the systemic nature of atherosclerosis. However, imaging of the coronaries is more complex than the carotids due to the small calibre, tortuosity and complex motion of these vessels. Nonetheless, rapid advances in spatial-resolution and image quality continue to address these challenges, making it likely that noninvasive coronary imaging will be used increasingly in future intervention trials.
Computed tomography calcium scoring
Coronary artery calcification is pathognomonic of coronary artery disease and the burden of calcification as measured by CT calcium scoring has been shown to correlate with cardiovascular risk [29] [30] [31] [32] . On this basis, coronary artery calcium scoring has been used as an end point in numerous trials investigating the effect of lipid lowering therapy. However, findings from these studies have been inconsistent, with some suggesting statins halt the progression of CT calcium scores whilst others have indicated the exact opposite [33] [34] [35] [36] . In a recent meta-analysis of eight intravascular imaging studies, aggressive statin therapy appeared overall to be associated with progression of coronary artery calcification, despite a reduction in soft plaque and total atheroma volume [37] . If coronary calcium scores predict adverse events, why do statins increase this score despite their well established clinical benefits? On an individual plaque basis, the heavily calcified plaques quantified by CT are generally stable and it is the mixed or noncalcified plaques that are more prone to rupture. Whilst the CT calcium score does not directly assess the plaques that will themselves rupture, it does provide a surrogate measure of the total plaque burden. The higher the calcium score the higher the plaque burden (including noncalcific plaque) and therefore the higher the risk of events. However, it is also likely that, in the context of drug therapy, increases in CT calcium may relate to a plaque stabilization effect and be associated with a reduced future risk of events. This important discrepancy highlights the difficulty in interpreting changes in the CT calcium score in clinical trials. More advanced imaging that directly visualizes the noncalcified or mixed atherosclerotic plaques prone to rupture and precipitate events is being developed.
Computed tomography coronary angiography
Computed tomography coronary angiography (CTCA) enables accurate noninvasive visualization of individual coronary plaques and their morphological characteristics. Importantly, it is able to visualize and quantify noncalcified plaque, providing key prognostic information. Whilst this approach was previously hampered by difficulties in contouring the vessel and plaque boundaries, automated postprocessing methods appear set to markedly simplify this process [38, 39] . CTCA also holds the ability to identify specific high-risk plaque characteristics including necrotic core, spotty calcification and positive remodelling. Identification of these characteristics provides yet further prognostic information [40] and may be modulated by lipid lowering therapy [41] . CTCA therefore appears set to play a major role in future clinical trials providing a direct assessment of the total plaque volume, noncalcified plaque volume and adverse coronary plaque characteristics in a single scan [42 && ]. Changes in these key parameters are likely to provide important insight as to the clinical efficacy of novel agents.
MRI of the coronary arteries
As imaging capabilities evolve, coronary MRI is gaining interest as an effective noninvasive imaging strategy to monitor the effects of therapeutic interventions on atherosclerosis. Recent advances in whole heart self-navigated coronary angiography techniques, combined with higher field strengths, novel contrast agents, sophisticated software for motion correction and rapid image acquisition, mean there is hope that MR may become an even more effective tool for coronary imaging in future intervention trials [43] .
Currently, one of the most promising MR techniques for coronary plaque imaging is the use of noncontrast T1-weighted imaging to identify methaemoglobin related to intracoronary thrombosis or intraplaque haemorrhage [44] . This T1-weighted MRI approach provides important prognostic information and, in an observational study, was used alongside CTCA to investigate the effect of intensive lipid lowering therapy on coronary plaque progression. The results demonstrated that pitavastatin treatment was associated with a significant reduction in plaque signal intensity (18.9% reduction; P < 0.001), a change which correlated with percentage reduction in total atheroma volume and high risk plaque features as assessed by CTCA [23 && ].
MOLECULAR IMAGING
Molecular imaging provides the opportunity to study many different aspects of disease activity, providing the ability to quantify early biological changes prior to the appearance of structural changes on anatomical imaging modalities (Fig. 2) [45, 46] .
Positron emission tomography
Positron emission tomography (PET) is an effective noninvasive imaging modality capable of monitoring disease activity at the molecular level through the detection of specific biological processes within tissues. The high sensitivity of PET imaging enables the detection of small metabolic changes potentially before any morphological changes become evident [47] , an advantage which can lead to early indications of therapeutic safety and efficacy. Numerous tracers, both novel and established, targeting specific characteristics of high-risk atherosclerosis have already been investigated in preclinical or clinical studies.
Fluorodeoxyglucose-positron emission tomography
The most established and widely used PET tracer is 18 F-fluorodeoxyglucose ( 18 F-FDG), a glucose analogue which enters glucose-utilizing cells and is unable to proceed through the glycolytic pathway, accumulating in proportion to cellular glycolysis. Whilst not entirely specific to inflammatory cells, use of this tracer exploits the increased metabolic activity of macrophages in comparison to surrounding cells. 18 F-FDG uptake, therefore, may be used as a surrogate for inflammation, providing an assessment of inflammatory plaque activity across multiple vascular beds [48] . Given the central role that inflammation plays in the progression of atherosclerosis, and in the precipitation of acute plaque rupture, it remains a key target for novel therapies. Indeed, this is the current subject of the Cardiovascular Inflammation Reduction Trial (CIRT) -Imaging Study (PI Zahi Fayad; NCT02576067). Histologically, the 18 F-FDG signal corresponds to macrophage density [49] , and multiple studies have proven its utility for detecting inflamed, potentially high-risk atherosclerotic disease in the carotids and large vessels [49, 50] . Data have established that 18 F-FDG uptake within the carotids and large vessels improves prediction of cardiovascular risk [51] , identifies the culprit lesion following transient ischaemic attacks and predicts recurrence of stroke [52, 53] . The high inter-observer reproducibility and low short-term inter-scan variability in FDG-PET measurements within the carotid arteries means that therapeutic drug effects can be demonstrated with a relatively small number of patients, and despite only small changes in standardized uptake value (SUV) or TBR measurements [47] . Indeed, reduction in the vascular 18 F-FDG signal has been demonstrated just 4 weeks following the commencement of statin therapy [54] .
These advantageous imaging characteristics have already been exploited in a number of phase II cardiovascular intervention trials, summarized in Table 2 [54] [55] [56] [57] [58] [59] [60] [61] , with FDG PET results demonstrating good agreement with the results of larger phase III trials examining clinical end points ( Table 2) . FDG-PET is therefore increasingly being used in clinical trials [48, 62, 63] .
Whilst promising for the study of inflammation and atherosclerosis within the large vessels and the systemic effects of anti-inflammatory agents, direct quantification of coronary arterial 18 F-FDG uptake has been more challenging. Glucose is also the predominant energy source of the myocardium, leading to a frequent observation of intense physiological uptake in the left ventricle, obscuring activity in the coronary vessels. Even despite dietary restriction that switches myocardial metabolism from glucose to free-fatty acid, coronary arterial uptake is unclear in over half of coronary territories [64 && ]. This has encouraged a search for more specific PET tracers to detect inflammation and alternative high-risk atherosclerotic disease processes including angiogenesis, hypoxia and microcalcification ( 
F-sodium fluoride
One alternative PET ligand which holds promise in future cardiovascular intervention trials is 18 F-sodium fluoride ( 18 F-NaF), a well established bone tracer which binds selectively to hydroxyapatite, detecting regions of calcification activity within the vasculature [70, 71] . Histological studies have confirmed its sensitivity and specificity for regions of newly developing microcalcification, a feature closely associated with unstable or vulnerable atherosclerosis [72, 73] . This radiotracer has been found to identify the culprit coronary vessel in over 90% of patients following myocardial infarction and, in patients with stable coronary artery disease, localizes to high-risk features on intravascular ultrasound and CT including positive remodelling, microcalcification and necrotic core [64 && ]. PET-CT imaging with 18 F-NaF has already been adopted as an exploratory end point in randomized trials, investigating the potential role of anticalcific therapy in halting the progression of aortic stenosis (NCT02132026). The adverse impact of calcification in aortic stenosis is clear. In atherosclerosis, further work is required to establish whether the 18 F-fluoride signal reduces with therapy and whether this is associated with an improvement in clinical outcomes. Nonetheless, this tracer has demonstrated the feasibility of using PET to measure disease activity in the coronary arteries.
Molecular magnetic resonance
MR also holds the ability to quantify disease activity at the molecular level and a number of targeted MR contrast agents have been investigated in preclinical and clinical studies. These include agents targeting elastin in the arterial wall [74] and fibrin within thrombus [75] . Perhaps the most advanced and promising of these techniques is the use of ultrasmall superparamagnetic particles of iron oxide (USPIO). Following their circulation within the blood pool, USPIOs are phagocytosed by inflammatory cells. Their pronounced T2/T2Ã shortening effect leads to focal regions of hypo-intensity on T2-weighted MR sequences, which may be used to identify regions of inflammation. In the carotid arteries, USPIO accumulation occurs in the majority of ruptured or high-risk plaques, and corresponds to areas of macrophage accumulation [76] . Similarly, USPIO-enhanced MR has been used to identify focal regions of inflammation within abdominal aortic aneurysms and appears to identify patients with more rapidly expanding aneurysms [77] .
USPIO-enhanced MR has already been used in intervention studies assessing the effects of existing anti-inflammatory therapies on carotid atherosclerosis. The ATHEROMA study randomized patients with carotid disease and USPIO accumulation to low-dose or high-dose atorvastatin and demonstrated a significant reduction in USPIO accumulation in those treated with high-dose statin following 3 months of therapy [46] .
FUTURE STRATEGIES: HYBRID IMAGING
The development of hybrid imaging strategies provides the opportunity to investigate each of the above features in a single scan, thereby providing a multiparametric assessment of the atherosclerotic disease process and an in-depth assessment of the efficacy of novel treatments. The increasing availability of PET/CT and, more recently, PET/MR imaging systems enables direct visualization of key pathological process and the accurate co-registration of biological activity to anatomical images during a single scan. Intervention trials have already utilized PET/CT systems to investigate treatment efficacy [54, 58] . It appears likely that, with greater availability, PET/MR will adopt a central role in the investigation of novel therapies, especially given the lower radiation burden and comprehensive imaging assessment offered by these scans. Indeed, we believe that, in the near future, carotid FDG-PET/MR will become the predominant imaging techniques used to assess drug efficacy in clinical trials. Not only does it offer the assessment of disease activity provided by PET, but also accurate measurement of plaque burden and composition provided by the MR. The effects of drug therapy on multiple different aspects of the atherosclerotic disease process will therefore be available from a single low-radiation imaging technique. Moreover, the excellent reproducibility of both MR and PET scanning means that relatively few patients would be required to detect even small therapeutic effects. Multiple time point studies may also be possible at acceptable radiation exposures.
Beyond the next few years, there is hope that coronary PET/CT imaging may reach the forefront of cardiovascular intervention trials, allowing direct assessments of drug efficacy in the coronary vasculature, wherein the majority of cardiac events arise. This will require continued development of postprocessing software and sophisticated motion correction techniques to overcome the challenges faced in coronary arterial PET. However, the development and validation of specific PET tracers for inflammation, microcalcification and other high-risk disease processes appears set to provide detailed assessments of coronary disease activity. These will complement measures of plaque burden and plaque morphology available on CTCA again providing multiparametric atherosclerotic plaque characterization.
CONCLUSION
In conclusion, rapid advances in imaging technology have provided the ability to directly visualize, quantify and monitor the effect of therapeutic interventions on atheroma burden, plaque composition and disease activity within the vasculature. With an expanding catalogue of novel therapies targeting multiple different aspects of the atherosclerotic disease process, early indicators of therapeutic efficacy 18 F fluoride uptake can predict future cardiac events (NCT02278211). 18 
F-FDG
Inflammation: macrophage glucose utilization Carotid aorta Strong correlation between FDG uptake and macrophage staining in carotid plaque (r ¼ 0.85; P < 0.0001) [50] ; CIRT (NCT02576067) trial ongoing and will use FDG-PET to measure changes in plaque activity in response to methotrexate therapy.
68Ga-DOTATATE Inflammation: SST receptor macrophages
Coronary; aorta carotid Uptake correlates with history of CV events and presence of calcified plaque [65] and can detect culprit lesions post-ACS with a sensitivity of 88% and specificity of 78% [66] ; VISION study ongoing to assess relationship between PET signal and carotid artery inflammation (NCT02021188). 18 
F-Choline Inflammation: macrophage choline metabolism
Aorta carotids ParisK study ongoing in order to assess relationship between 18 F-choline uptake and carotid artery inflammation using PET/CT and MRI (NCT01899014). 18 
F-FMISO Hypoxia Aorta
Strong accumulation in atherosclerotic rabbit aortas and uptake increases with progression of atherosclerosis [67] .
[(18)F]Galacto-RGD Neoangiogenesis: avb3 integrin Aorta carotid Increased uptake in stenotic carotid arteries which correlated with avb3 integrin expression, though in small patient numbers [68] .
11C-PK11195
Inflammation: translocator protein expressed by activated macrophages Carotid Increased uptake in symptomatic vs. asymptomatic carotid stenosis. PPV of 100% for detecting symptomatic plaque when PET signal combined with CT attenuation [69] .
ACS, acute coronary syndrome; CV, cardiovascular; FDG-PET, fluorodeoxyglucose-positron emission tomography; PPV, positive predictive value.
and safety are of critical importance prior to the initiation of phase III outcome studies. Noninvasive imaging modalities have already played a valuable role in our understanding of drug effects and, with the advent of hybrid imaging, offer comprehensive multiparametric assessments of drug efficacy. These approaches are likely to play an expanding role in the testing and development of novel atherosclerotic therapies.
